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Background: Nucleobindin 2 (NUCB2) protein, a novel oncoprotein, is overexpressed in breast cancer. To date,
there have been no published data regarding the role of NUCB2 protein expression in prostate cancer (PCa).
Therefore, this study was performed to investigate the correlations between NUCB2 protein expression and
prognosis in patients with PCa.
Methods: Through immunohistochemistry, NUCB2 protein expression was evaluated in 60 benign prostatic
hyperplasia (BPH) specimens and 180 PCa specimens. The correlation of NUCB2 protein expression with
clinicopathological parameters was assessed using χ2 analysis. Kaplan-Meier analysis and Cox proportional hazards
regression models were used to investigate the correlation between NUCB2 protein expression and prognosis of
PCa patients.
Results: The immunohistochemistry results showed that the expression level of NUCB2 in PCa cases was
significantly higher than that in BPH tissues (P < 0.001). Moreover, statistical analysis also showed that high NUCB2
protein expression was positively related to seminal vesicle invasion, lymph node metastasis, angiolymphatic
invasion, higher Gleason score, biochemical recurrence (BCR), and higher preoperative prostate-specific antigen
(PSA). Furthermore, it was also shown that patients with high NUCB2 protein expression had significantly poorer
overall survival and BCR- free survival compared with patients with low expression of NUCB2 protein. Multivariate
Cox regression analysis revealed that high NUCB2 protein expression level was an independent prognostic factor
for overall survival and BCR-free survival of patients with PCa.
Conclusions: NUCB2 protein expression showed a strong association with the potencies of BCR and progression of
PCa, and that may be applied as a novel biomarker for the prediction of BCR, and helpful for improving the
diagnosis, prognosis and treatment of PCa.Background
Prostate cancer (PCa) is the most frequently diagnosed
male cancer and the second leading cause of cancer
death in men in the United States [1]. Despite the un-
ceasing biomedical research efforts, PCa continues to
pose a major public health problem [2]. Serum prostate-
specific antigen (PSA), as it is universally known, still re-
mains, in spite of the ongoing criticism, one of the most
extensively applied PCa biomarkers [3,4]. Although we* Correspondence: xymnwk@163.com
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stated.have made considerable advances in diagnosis and adju-
vant therapy of PCa, many patients develop metastases,
the overall survival rate of PCa patients has not been im-
proved markedly. Although some clinical parameters,
such as serum PSA levels and Gleason score, may pro-
vide some prognostic utility in the treatment settings,
there are currently no definitive clinical methods that
can reliably predict the responses to clinical therapies
for PCa [5-9]. Therefore, it is necessary to identify novel
PCa markers to strengthen the efficiency of early diagno-
sis and to improve the therapeutic strategies of this dis-
ease. Evaluation of the expression and role of these
proteins in PCa is required for defining molecular and
cellular factors associated with PCa aggressiveness andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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interventions, identifying novel PCa biomarkers.
The nucleobindin 2 (NUCB2) gene comprises 14
exons spanning 54,785 nucleotides, with an mRNA of
1,612 nucleotides, of which only nucleotides 246 to
1,508 are translated. The NUCB2 protein contains a 24-
amino acid putative signal peptide sequence followed by
a 396-amino acid sequence, with very high amino acid
sequence homology among rat, mouse, and human spe-
cies (> 85%) [10]. Structural analyses revealed the pres-
ence of several conserved cleavage recognition sites for
prohormone convertases within rat NUCB2 sequence,
thus suggesting this to be a precursor that gives rise, by
differential proteolytic processing, to several active pep-
tides. NUCB2 is proteolytically processed by prohormone
to produce at least three peptides, nesfatin-1, nesfatin-2,
and nesfatin-3. NUCB2 has a characteristic constitution of
functional domains, such as a signal peptide, a Leu/Ile rich
region, two Ca2+ binding EF-hand domains separated by
an acidic amino acid-rich region, and a leucine zipper
[11,12], and has a wide variety of basic cellular functions
[13-15]. NUCB2 is known to mainly express in key hypo-
thalamic nuclei with proven roles in energy homeostasis
[13]. Moreover, recent investigations have indicated that
NUCB2 is also expressed in various human peripheral
tissues, including the stomach, pancreas, reproductive
organs, and adipose tissues, with relevant metabolic func-
tions, suggesting that NUCB2 signaling might participate
in adaptative responses and in the control of body func-
tions gated by the state of energy reserves [16].
Protein products of NUCB2 gene have been studied in
tumors arising from breast, and stomach [17,18]. To
date, no reports investigated the impact of NUCB2 pro-
tein expression on the prognosis of patients with PCa.
Therefore, the NUCB2 protein expression was measured
in PCa tissues and benign prostatic hyperplasia (BPH)
tissues by and immunohistochemistry. We studied the
correlation between the relative expression of NUCB2
protein and clinicopathological parameters to evaluate its
clinical significance. Additionally, we assessed whether
NUCB2 protein expression can be used as an independent
biomarker for BCR and prognosis of patients with PCa.
Materials and methods
Patient and tissue samples
Written informed consent was obtained from all of the
patients. The research ethics committee of Tianjin med-
ical university approved the study (TMUhMEC2012015).
Formalin-fixed paraffin-embedded samples were obtained
from 180 patients with PCa and 60 patients with BPH tis-
sues from patients who were surgically treated in the sec-
ond hospital of Tianjin medical university, China, between
1999 and 2010. Before radical prostatectomy, none of the
PCa patients had received neoadjuvant chemotherapy,androgen deprivation treatment, radiation therapy or
immunotherapy. Inclusion criteria were the availability
of suitable paraffin blocks for IHC and follow-up in-
formation. The histopathology of each specimen was
reviewed on the hematoxylin-eosin-stained tissue sec-
tion to confirm diagnosis. The following biochemical
and pathological parameters were recorded: preopera-
tive PSA, Gleason score, PCa stage, lymph node status,
angiolymphatic invasion status, surgical margin status,
and seminal vesicle invasion status. The TNM staging sys-
tem was used to describe the extent of PCa in patients
(based on the AJCC Cancer Staging Manual, Seventh
Edition, 2010, Springer New York, Inc.). The time to bio-
chemical relapse was defined as the period between surgi-
cal treatment and the measurement of two successive
values of serum PSA level ≥ 0.2 ng/ml. Overall survival
was defined as the period from the end of treatment to
death or the time of the last follow-up.
Immunohistochemical staining
NUCB2 immunostaining was performed for all speci-
mens using tissues obtained before treatment. Formalin-
fixed, paraffin-embedded tissues were sectioned at 3 μm.
The sections were de-waxed in xylene and rehydrated in
graded ethanol. Novocastra peroxidase (3% hydrogen per-
oxide) was used to neutralize endogenous peroxidase ac-
tivity of the samples for 10 min. NUCB2 staining was
carried out by using rabbit polyclonal antibody (Sigma-
Aldrich) at a 1:250 dilution, and the samples were in-
cubated for 30 min at 25°C. To reveal the binding of
primary antibody by peroxidase staining, the substrate/
chromogen, 3,3-diaminobenzidine (DAP), prepared from
Novocastra DAP Chromogen and NovaLink DAP Sub-
strate Buffer (Polymer) were used. Finally, the sections
were counterstained with hematoxylin, dehydrated, and
cleared with xylene, and the sections were mounted for
examination. Normal rabbit IgG was used instead of the
primary antibody, as a negative control of NUCB2 immu-
nostaining. Human tissue of the breast cancer was used as
a positive control for NUCB2 antibody.
Staining assessment
All of the samples were independently evaluated by two
pathologists, who were experienced in evaluating immu-
nohistochemistry and blinded to the clinicopathologic
information of these patients. NUCB2 protein expression
levels were classified semiquantitatively combining the
proportion and intensity of positively stained immunore-
active cells [19]. The percentage of positive-staining tumor
cells was scored as follows: 0 (< 5% positive tumor cells), 1
(5-50% positive tumor cells), and 2 (>50% positive tumor
cells). Staining intensity was scored as follows: 0 (no stain-
ing or only weak staining); 1 (moderate staining); and 2
(strong staining). The sum of the staining intensity score
Table 1 Expression of NUCB2 protein in prostate
specimens
Groups n NUCB2 protein expression % P
High expression
BPH 60 4 6.67% < 0.001
PCa 180 101 56.11%
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protein expression levels: 0-2, low expression and 3-4, high
expression. Cases with discrepancies were re-reviewed sim-
ultaneously by the original two pathologists and a senior
pathologist until a consensus was reached.
Statistical analysis
The χ2 test was used to analyze the relationship between
the NUCB2 protein expression and the clinicopathologi-
cal characteristics. Survival curves were plotted using
the Kaplan-Meier method and compared using theFigure 1 Immunohistochemical staining for NUCB2 in PCa and benign
protein expression was found in cytoplasm of PCa tissues. (B) Low NUCB2
weakly positive staining was found in cytoplasm of benign prostate tissue.
antibody omitted in PCa tissues.log-rank test. Survival data were evaluated using uni-
variate and multivariate Cox regression analyses. All stat-
istical analyses were performed using SPSS version 17.0. A
p value <0.05 was considered to be statistically significant.
Results
NUCB2 protein is overexpressed in PCa tissues
A total of 180 PCa patients and 60 BPH patients who
were qualified with the inclusion criteria were included
in the study. NUCB2 protein expression was high in
4 (6.67%) of 60 patients with BPH and 101 (56.11%)
of 180 patients with PCa. NUCB2 protein expression
was overexpressed in PCa tissues compared with the
BPH tissues, and the difference was statistically significant
(P < 0.001) (Table 1). As shown in Figure 1, the NUCB2
staining was localized within the cytoplasm of immu-
noreactive prostate cells. In the positive control, NUCB2
was mainly positive in the cytoplasm of breast carcinoma
cells (Figure 2).prostate tissue (original magnification ×200). (A) High NUCB2
protein expression was found in cytoplasm of PCa tissues. (C) NUCB2
(D) Negative immunostaining of negative controls with the primary
Figure 2 Positive immunostaining of positive controls in breast
cancer tissues (original magnification ×200).
Zhang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:77 Page 4 of 8
http://www.jeccr.com/content/32/1/77Association of NUCB2 protein expression with the
clinicopathological variables of PCa
We investigated the association between NUCB2 protein
expression status and commonly used clinicopathologi-
cal variables in PCa. The associations between NUCB2
protein expression and clinicopathological variables are
shown in Table 2. High expression of NUCB2 protein
was significantly associated with seminal vesicle invasion
(P = 0.016), the higher level of preoperative PSA (P =
0.006), positive lymph node metastasis (P = 0.022), the
positive angiolymphatic invasion (P = 0.042), BCR, and
the higher Gleason score (P = 0.017). However, the
NUCB2 protein expression was not associated with age,
pathological stage, and surgical margin status.
Correlation of NUCB2 protein expression with BCR-free
survival
To investigate the prognostic value of NUCB2 for PCa,
we assessed the association between the NUCB2 protein
expression and the BCR-free survival duration using a
Kaplan–Meier analysis with a log-rank test. The log-
rank test showed that the BCR-free survival time of pa-
tients with PCa was significantly different between the
groups with high NUCB2 protein expression and low
NUCB2 protein expression. In patients with PCa, the
high NUCB2 protein expression group had a shorter sur-
vival duration compared to the low NUCB2 protein ex-
pression group. Univariate analysis with Cox proportional
hazards model identified 3 prognostic factors: seminal
vesicle invasion (P = 0.005), Gleason score (P < 0.001),
and NUCB2 protein expression (P < 0.001). The other
clinicopathological features, such as age, preoperativePSA, angiolymphatic invasion, lymph node metastasis,
surgical margin status, and pathological stage were not
statistically significant prognosis factors. By multivariate
analysis, we showed that NUCB2 protein expression (P <
0.001), seminal vesicle invasion (P = 0.003), and Gleason
score (P < 0.001) were independent prognostic factors for
BCR-free survival of PCa patients. The detailed results are
present in Table 3.
Correlation of NUCB2 protein expression with overall
survival
To examine the impact of NUCB2 protein overexpression
on the overall survival, we first performed univariate ana-
lysis of traditional clinicopathologic variables for progno-
sis. Significant variables in the overall survival analysis
included NUCB2 expression (P < 0.001), PCa stage (P <
0.001), Gleason score (P < 0.001), and preoperative PSA
(P = 0.001). Multivariate Cox regression analysis enrolling
above-mentioned significant parameters showed that
NUCB2 protein expression (P < 0.001), PCa stage (P <
0.001), Gleason score (P < 0.001), and preoperative PSA
(P < 0.001) were independent prognostic factors for over-
all survival of patients with PCa. The detailed results are
shown in Table 4.
Discussion
PCa is not a single disease, but an umbrella under which a
plethora of heterogeneous diseases is hidden. These range
from indolent localized tumors, to aggressive metastatic
diseases [20-22]. Metastatic hormone-refractory PCa is
the most aggressive form, and is generally associated with
very poor prognosis. An accurate and early diagnosis
is essential for efficient management of PCa [23-25].
Therefore, to complement improvements in the clinical
management, substantial progress in the diagnostic path-
way of PCa is urgently needed [26-28]. So evaluation of
the expression and role of potential proteins in PCa is re-
quired for defining molecular and cellular factors associ-
ated with PCa aggressiveness and therapy resistance,
developing more effective therapeutic interventions, and
identifying novel PCa biomarkers.
Our previous reports indicated that NUCB2 mRNA was
upregulated in PCa tissues [29,30]. The data revealed that
NUCB2 mRNA may be an independent prognostic factor
for BCR-free survival in patients with PCa [29,30]. To date,
the associations between NUCB2 protein overexpression
and the prognosis of PCa have not been reported. This is
the first study to investigate the impact of NUCB2 protein
overexpression on the prognosis of PCa based on a rela-
tively large number of clinical samples. In this study, we
analyzed NUCB2 protein expression in 180 patients with
PCa using immunohistochemistry. We demonstrated, here,
that NUCB2 is overexpressed in a large proportion of
patients with PCa and high NUCB2 protein expression
Table 2 Clinicopathologic variables and NUCB2 protein expression in 180 PCa patients
Variable Group NUCB2 protein expression P value
n High Low
Age 0.897
<70 97 54 (55.7%) 43 (44.3%)
≥70 83 47 (56.6%) 36 (43.4%)
Lymph node metastasis 0.022
Positive 17 14 (82.4%) 3 (17.6%)
Negtive 163 87 (53.4%) 76 (46.6%)
Surgical margin status 0.521
Positive 14 9 (64.3%) 5 (35.7%)
Negtive 166 92 (55.4%) 74 (44.6%)
Seminal vesicle invasion 0.016
Positive 35 26 (74.3%) 9 (25.7%)
Negtive 145 75 (51.8%) 70 (48.3%)
PCa stage 0.114
T1 103 63 (61.2%) 40 (38.8%)
T2/T3 77 38 (49.4%) 39 (50.6%)
Preoperative PSA 0.006
<4 5 1 (20%) 4 (80%)
4-10 64 28 (43.8%) 36 (56.2%)
>10 111 72 (64.9%) 39 (35.1%)
Gleason score 0.017
<7 99 47 (47.5%) 52 (52.5%)
7 34 20 (58.8%) 14 (41.2%)
>7 47 34 (72.3%) 13 (27.7%)
Angiolymphatic invasion 0.042
Positive 35 25 (71.4%) 10 (28.6%)
Negtive 145 76 (52.4%) 69 (47.6%)
Biochemical recurrence 0.003
Absence 128 63 (49.2%) 65 (50.8%)
Presence 52 38 (73.1%) 14 (26.9%)
Table 3 Prognostic value of NUCB2 protein expression for the BCR-free survival in univariate and multivariate analyses
by Cox regression
Covariant Univariate analysis Multivariate analysis
Exp (B) 95% CI P value Exp (B) 95% CI P value
NUCB2 protein expression (high/low) 2.306 1.501-3.544 <0.001 2.535 1.643-3.911 <0.001
Gleason score (> 7/7/< 7) 1.703 1.280-2.265 <0.001 1.846 1.384-2.460 <0.001
PSA (>10/4-10/< 4) 1.241 0.705-2.188 0.454
Age (≥65/< 65) 1.068 0.804-1.419 0.650
Angiolymphatic invasion (presence/absence) 1.084 0.814-1.443 0.580
Surgical margin status (presence/absence) 1.017 0.709-1.459 0.925
PCa Stage (T2, T3/T1) 1.090 0.921-1.291 0.316
Lymph node metastasis (presence/absence) 1.140 0.850-1.528 0.381
Seminal vesicle invasion (presence/absence) 1.505 1.132-2.003 0.005 1.538 1.154-2.048 0.003
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Table 4 Prognostic value of NUCB2 protein expression for the overall survival in univariate and multivariate analyses
by Cox regression
Covariant Univariate analysis Multivariate analysis
Exp (B) 95% CI P value Exp (B) 95% CI P value
NUCB2 protein expression (high/low) 2.978 1.516-6.181 <0.001 3.152 1.317-6.214 <0.001
Gleason score (> 7/7/< 7) 2.526 1.788-3.568 <0.001 2.014 1.217-2.869 <0.001
PSA (>10/4-10/< 4) 2.034 1.338-23.092 0.001 1.989 1.292-3.053 <0.001
Age (≥65/< 65) 1.282 0.917-1.792 0.146
Angiolymphatic invasion (presence/absence) 1.373 0.813-2.319 0.235
Surgical margin status (presence/absence) 1.101 0.703-1.724 0.674
PCa Stage (T2, T3/T1) 4.131 2.888-5.911 <0.001 3.671 2.656-5.715 <0.001
Lymph node metastasis (presence/absence) 1.044 0.746-1.462 0.800
Seminal vesicle invasion (presence/absence) 1.358 0.956-1.928 0.087
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outcome in PCa. Furthermore, NUCB2 proved to be an in-
dependent molecular biomarker of prognosis in PCa and
may become a novel molecular target in the strategies for
the prognosis of this disease.
We analyzed the association between NUCB2 protein
expression and traditional clinicopathogical characteris-
tics in PCa. We observed that the NUCB2 protein levels
were significantly higher in PCa tissues compared to
those in BPH tissues. We also found that expression of
NUCB2 protein expression was significantly associated
with seminal vesicle invasion, the higher level of pre-
operative PSA, positive lymph node metastasis, the posi-
tive angiolymphatic invasion, BCR, and the higher
Gleason score. These observations support the hypoth-
esis that NUCB2 may function as an oncogene in PCa
and that NUCB2 may play an important role in the
tumorigenesis of PCa. The data showed that NUCB2
protein overexpression was associated with poor overall
and BCR-free survival. These results suggest that high
NUCB2 protein expression plays an important role in
the progression of PCa and is significantly associated
with a poor prognosis independently of other factors.
This raises the possibility that NUCB2 may be a prog-
nostic parameter for PCa that is as or more reliable than
the clinicopathologic factors currently in use and sug-
gests the possibility to use NUCB2 in individualization
of both patient prognosis and therapy.
In the Kaplan–Meier survival analysis, the BCR-free
survival period of patients with PCa with high NUCB2
protein expression was significantly shorter than that of
patients with low NUCB2 expression. Univariate ana-
lyses showed that high NUCB2 protein expression in
PCa is significantly associated with the BCR-free survival
rate. Moreover, multivariate analysis demonstrated that
high NUCB2 protein expression is an independent risk
factor in the prognosis of PCa patients. These resultssuggest that the detection of increased NUCB2 protein
expression might help identify PCa patients with a poor
prognosis and could, therefore, be a novel prognostic
marker for PCa patients. The precise molecular mecha-
nisms behind the altered expression of NUCB2 in PCa
are unclear. Additional studies to investigate the real
molecular mechanisms of altered expression of NUCB2
in the development or progression of PCa are essential.
Currently, the advantages of serum PSA as a general
PCa biomarker are viewed with intense skepticism [31,32].
A variety of algorithms and nomograms that calculate the
probabilities of overall and BCR-free survival after treat-
ment have been used in order to direct clinicians into
the most suitable treatment options for PCa patients
[33]; nonetheless patients still present unforeseen disease
course patterns. The present study shows that NUCB2
protein expression can improve PCa management by mak-
ing available important and independent differential prog-
nostic information. The results indicated that NUCB2
could constitute a molecular prognostic biomarker for
PCa patients, identifying who are more likely to have
higher risk of BCR and need receive a more aggressive
treatment. Our findings could help establish a more per-
sonalized medicine-focused approach.
Our study has some limitations. The sample size is not
large enough. To solve this problem, a randomized study
investigating the association between NUCB2 protein
expression and prognosis should be conducted to con-
firm whether NUCB2 could be used as a novel predictor
of overall survival and BCR-free survival. Advanced
castration-resistant PCa has not been studied in this
study. We will study whether NUCB2 protein expression
can provide significant information for the differential
discrimination of early localized disease from advanced
castration-resistant PCa patients in future. In summary,
this is the first study to show an association between
NUCB2 protein overexpression and PCa. The results
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pendent factor in overall survival and BCR-free survival
prognosis and that it may be an important biomarker.
Conclusions
Taken together, high NUCB2 protein expression in PCa is
strongly correlated with seminal vesicle invasion, lymph
node metastasis, angiolymphatic invasion, Gleason score,
and preoperative PSA. The present results revealed that
NUCB2 is an independent prognostic factor for overall
survival and BCR-free survival in patients with PCa. Our
findings suggest that NUCB2 protein might be used as a
new biomarker and a potential therapeutic target for PCa.
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